447 related articles for article (PubMed ID: 28780343)
1. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.
Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT;
Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of anticoagulation selection for acute venous thromboembolism.
Badreldin H; Nichols H; Rimsans J; Carter D
J Thromb Thrombolysis; 2017 Jan; 43(1):74-78. PubMed ID: 27592341
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
7. The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry.
Guercini F; Mommi V; Camporese G; Tonello C; Imberti D; Benedetti R; De Bartolomeo G; Di Lecce L; Romeo F; Agnelli G
Intern Emerg Med; 2016 Dec; 11(8):1095-1102. PubMed ID: 27448310
[TBL] [Abstract][Full Text] [Related]
8. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
Cohen AT; Gitt AK; Bauersachs R; Fronk EM; Laeis P; Mismetti P; Monreal M; Willich SN; Bramlage P; Agnelli G; Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT
Thromb Haemost; 2017 Jun; 117(7):1326-1337. PubMed ID: 28405675
[TBL] [Abstract][Full Text] [Related]
9. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos AC; Turpie AG
Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
[TBL] [Abstract][Full Text] [Related]
11. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
12. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
[TBL] [Abstract][Full Text] [Related]
13. Persistence to direct oral anticoagulants for acute venous thromboembolism.
Dronkers CEA; Lijfering WM; Teichert M; van der Meer FJM; Klok FA; Cannegieter SC; Huisman MV
Thromb Res; 2018 Jul; 167():135-141. PubMed ID: 29843087
[TBL] [Abstract][Full Text] [Related]
14. Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center.
Patel SM; Wang T; Outler DL; Elliott J; Knauss M; Peasah SK; Akbashev M
J Thromb Thrombolysis; 2020 Feb; 49(2):287-293. PubMed ID: 31598931
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
Comerota AJ; Ramacciotti E
Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
[TBL] [Abstract][Full Text] [Related]
16. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns.
Ghanima W; Schultze A; Donaldson R; Brodin E; Halvorsen S; Graham S; Carroll R; Ulvestad M; Lambrelli D
Clin Ther; 2021 Jul; 43(7):1179-1190.e3. PubMed ID: 34083030
[TBL] [Abstract][Full Text] [Related]
17. What have we learned from real-world NOAC studies in venous thromboembolism treatment?
Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():83-91. PubMed ID: 29407632
[TBL] [Abstract][Full Text] [Related]
18. The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines.
Rojas-Hernandez CM
Support Care Cancer; 2018 Mar; 26(3):711-720. PubMed ID: 29188376
[TBL] [Abstract][Full Text] [Related]
19. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension.
Benzidia I; Robitaille C; Abualsaud A; McDonald L; Lesenko L; Morin JF; Langleben D; Kahn SR; Hirsch A
Thromb Res; 2023 Sep; 229():139-145. PubMed ID: 37453256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
